SARS-CoV-2 triggers the production of the antiviral protein IFN-γ, which is associated with fatigue, muscle ache and depression. New research shows that in Long COVID patients, IFN-y production persists until symptoms improve, highlighting a potential biomarker and a target for therapies.
Manufacturing roundup: Aurisco completes FDA inspection of ingredient production site; NIH picks Exothera to develop nasal Covid vaccine
Aurisco Pharmaceutical said Tuesday that the FDA gave it the green light to produce active pharmaceutical ingredients (APIs) at a manufacturing site in Yangzhou, China.
August 18, 2023